These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7800431)

  • 1. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis.
    Amin N; Dozor AJ
    Pediatr Pulmonol; 1994 Sep; 18(3):150-4. PubMed ID: 7800431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
    Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
    Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of rhDNase on the respiratory function and nutritional status of children and adolescents with mucoviscidosis].
    Wizla-Derambure N; Michaud L; Sardet A; Deschildre A; Loeuille GA; Tassin E; Loire N; Buisine C; Boutry E; Dias J; Hecquet F; Turck D
    Arch Pediatr; 1998 Apr; 5(4):378-83. PubMed ID: 9759156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
    Hodson M
    Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
    Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
    Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
    Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
    N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
    Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
    Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
    Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A six-month study of growth and energy expenditure in children with cystic fibrosis taking a pulmonary inhalation medication (rhDNase).
    Fung EB; Barden EM; Wasserman D; Zemel BS; Heinrich BT; Scanlin TF; Stallings VA
    J Am Coll Nutr; 1999 Aug; 18(4):330-8. PubMed ID: 12038476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective review of the effects of rhDNase in children with cystic fibrosis.
    Davies J; Trindade MT; Wallis C; Rosenthal M; Crawford O; Bush A
    Pediatr Pulmonol; 1997 Apr; 23(4):243-8. PubMed ID: 9141109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
    Eisenberg JD; Aitken ML; Dorkin HL; Harwood IR; Ramsey BW; Schidlow DV; Wilmott RW; Wohl ME; Fuchs HJ; Christiansen DH; Smith AL
    J Pediatr; 1997 Jul; 131(1 Pt 1):118-24. PubMed ID: 9255202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
    Suri R; Metcalfe C; Wallis C; Bush A
    Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
    Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
    Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
    Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
    Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.
    Fiel SB; Fuchs HJ; Johnson C; Gonda I; Clark AR
    Chest; 1995 Jul; 108(1):153-6. PubMed ID: 7606951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
    Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
    Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
    Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
    Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.